^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PIGF inhibitor

    Related drugs:
    21h
    INTRAMED-CRVO: Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion (clinicaltrials.gov)
    P4, N=51, Completed, University of Athens
    New P4 trial
    9d
    Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E (clinicaltrials.gov)
    P4, N=30, Completed, The University of Hong Kong | Recruiting --> Completed | N=64 --> 30
    Trial completion • Enrollment change
    |
    Eylea (aflibercept intravitreal)
    9d
    Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) (clinicaltrials.gov)
    P3, N=35, Active, not recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    11d
    Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study (clinicaltrials.gov)
    P2, N=30, Completed, Moorfields Eye Hospital NHS Foundation Trust | Unknown status --> Completed
    Trial completion
    14d
    SPECTRUM-US: An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (clinicaltrials.gov)
    P=N/A, N=800, Not yet recruiting, Regeneron Pharmaceuticals
    New trial • Real-world evidence • Real-world
    |
    Eylea (aflibercept intravitreal)
    15d
    Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=32, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Initiation date: Oct 2023 --> Feb 2024
    Trial initiation date • Metastases
    |
    Libtayo (cemiplimab-rwlc) • Zaltrap (ziv-aflibercept IV)
    16d
    VISION-AF: A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema (clinicaltrials.gov)
    P4, N=100, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    28d
    Proteomic study of vitreous in proliferative diabetic retinopathy patients after treatment with aflibercept: a quantitative analysis based on 4D label-free technique. (PubMed, Int J Ophthalmol)
    Proteomic analysis is an approach of choice to explore the molecular mechanisms of PDR. Our data show that multiple proteins are differentially changed in PDR patients after intravitreal injection of aflibercept, among which C1QTNF5, CLU, TIMP1 and SIRPα may become targets for future treatment of PDR and resolution of anti-VEGF resistance.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CLU (Clusterin) • SIRPA (Signal Regulatory Protein Alpha)
    30d
    Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Singapore National Eye Centre | Recruiting --> Active, not recruiting | N=160 --> 60
    Enrollment closed • Enrollment change
    |
    Visudyne (verteporfin)
    1m
    One Year Trial Evaluating Safety of Ozurdex With Eylea (clinicaltrials.gov)
    P4, N=50, Completed, Texas Retina Associates | Unknown status --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    1m
    FIREFLEYE next: Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 (clinicaltrials.gov)
    P3, N=96, Active, not recruiting, Bayer | Trial completion date: Jul 2025 --> Oct 2025 | Trial primary completion date: Jul 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    2ms
    ALVOEYE-D: Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease (clinicaltrials.gov)
    P3, N=35, Active, not recruiting, Alvotech Swiss AG | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity (clinicaltrials.gov)
    P4, N=12, Completed, Seoul National University Hospital
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment (clinicaltrials.gov)
    P4, N=17, Terminated, Wake Forest University Health Sciences | N=10 --> 17 | Trial completion date: Aug 2024 --> Dec 2023 | Suspended --> Terminated | Trial primary completion date: Jun 2024 --> Dec 2023; IRB stopped study due to safety concerns. No further data collection and what has been collected is not appropriate for analysis.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    VEGFA (Vascular endothelial growth factor A)
    |
    Eylea (aflibercept intravitreal)
    2ms
    An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK) (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Bayer
    New trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    PULSOV: Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Fondation Ophtalmologique Adolphe de Rothschild | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    2ms
    Mean Visual Acuity Changes Following Five Injections of Aflibercept (clinicaltrials.gov)
    P=N/A, N=48, Active, not recruiting, McMaster University | Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    2ms
    Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial (clinicaltrials.gov)
    P4, N=64, Recruiting, Tianjin Medical University Eye Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    2ms
    ALVOEYE-D: Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease (clinicaltrials.gov)
    P3, N=35, Recruiting, Alvotech Swiss AG | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. (PubMed, Cancer Med)
    The combination of sapanisertib and ziv-aflibercept was generally tolerable and demonstrated anti-tumor activity in heavily pre-treated patients with advanced malignancies.
    P1 data • Journal • Combination therapy • Metastases
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)
    3ms
    Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=83, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Jan 2024
    Trial completion • Trial completion date • Combination therapy • Surgery • Metastases
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)
    3ms
    The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema (clinicaltrials.gov)
    P=N/A, N=2500, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence • Real-world
    3ms
    ALVOEYE-D: Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease (clinicaltrials.gov)
    P3, N=35, Not yet recruiting, Alvotech Swiss AG | Initiation date: Nov 2023 --> Mar 2024 | Trial primary completion date: Feb 2024 --> May 2024
    Trial initiation date • Trial primary completion date
    3ms
    FAR-WEST: Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Nantes University Hospital
    New trial
    |
    Lucentis (ranibizumab)
    3ms
    PULSOV: Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Fondation Ophtalmologique Adolphe de Rothschild | Trial completion date: May 2024 --> Mar 2025 | Trial primary completion date: May 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    3ms
    The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema (clinicaltrials.gov)
    P=N/A, N=2500, Not yet recruiting, Bayer | Trial completion date: Jun 2028 --> Jan 2028
    Trial completion date • Real-world evidence • Real-world
    3ms
    Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=83, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date • Combination therapy • Surgery • Metastases
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)
    3ms
    Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab (clinicaltrials.gov)
    P=N/A, N=13, Completed, Rigshospitalet, Denmark
    New trial
    |
    Eylea (aflibercept intravitreal) • Lucentis (ranibizumab)
    4ms
    A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection (clinicaltrials.gov)
    P=N/A, N=140, Completed, Sanofi | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)
    4ms
    Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment. (PubMed, Cancer Immunol Immunother)
    Although limited by sample size and follow-up, these findings highlight the potential of the combination of ziv-aflibercept antiangiogenic therapy with pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment and the need for further research to improve outcomes in anti-PD-1-resistant melanoma.
    Journal • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    Keytruda (pembrolizumab) • Zaltrap (ziv-aflibercept IV)
    4ms
    FAN: Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=70, Active, not recruiting, Medical University of Graz | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Oct 2024
    Enrollment closed • Trial primary completion date
    |
    VEGFA (Vascular endothelial growth factor A)
    |
    Eylea (aflibercept intravitreal)
    4ms
    Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) (clinicaltrials.gov)
    P2, N=50, Recruiting, Innostellar Biotherapeutics Co.,Ltd
    New P2 trial • Gene therapy
    |
    Eylea (aflibercept intravitreal)
    5ms
    Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    CD8 (cluster of differentiation 8) • HGF (Hepatocyte growth factor) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • FGF (Fibroblast Growth Factor) • MLANA (Melan-A)
    |
    Keytruda (pembrolizumab) • Zaltrap (ziv-aflibercept IV)
    5ms
    Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent (clinicaltrials.gov)
    P1, N=30, Recruiting, Panolos Bioscience
    Trial completion date • Trial primary completion date • Immunomodulating • Metastases
    |
    FLT1 (Fms-related tyrosine kinase 1)
    |
    PB101
    5ms
    Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment (clinicaltrials.gov)
    P4, N=10, Suspended, Wake Forest University Health Sciences | Trial completion date: Feb 2024 --> Aug 2024 | Recruiting --> Suspended | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial suspension • Trial primary completion date
    |
    VEGFA (Vascular endothelial growth factor A)
    |
    Eylea (aflibercept intravitreal)
    5ms
    Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments (clinicaltrials.gov)
    P=N/A, N=46, Completed, Rigshospitalet, Denmark | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    6ms
    A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022 (clinicaltrials.gov)
    P=N/A, N=155413, Completed, Regeneron Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    6ms
    The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema (clinicaltrials.gov)
    P=N/A, N=2500, Not yet recruiting, Bayer | Trial completion date: Jan 2028 --> Jun 2028
    Trial completion date • Real-world evidence • Real-world
    |
    Eylea (aflibercept intravitreal)
    6ms
    Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration (clinicaltrials.gov)
    P1, N=45, Not yet recruiting, Caregen Co. Ltd.
    New P1 trial
    |
    Eylea (aflibercept intravitreal)
    6ms
    Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments (clinicaltrials.gov)
    P=N/A, N=58, Active, not recruiting, Rigshospitalet, Denmark
    New trial
    |
    Eylea (aflibercept intravitreal)
    6ms
    Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=32, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
    New P2 trial • Metastases
    |
    Libtayo (cemiplimab-rwlc) • Zaltrap (ziv-aflibercept IV)
    7ms
    XTEND: Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease (clinicaltrials.gov)
    P=N/A, N=1563, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion